Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab after concurrent chemoradiotherapy versus chemoradiotherapy alone in limited-stage small-cell lung cancer
2017-004572-62Phase 2Active
- Sponsor
- Norwegian University of Science and Technology
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of atezolizumab in small cell lung cancer (SCLC) (2 arms), sponsored by Norwegian University of Science and Technology. Primary endpoint: 2-year survival. Started Mar 2018; status: active.
02
Drugs
atezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2017-004572-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004572-62.